Does Repository Corticotropin Interact with Hyaluronidase?
CDI records a moderate classification for Repository Corticotropin and Hyaluronidase. The stored summary is: Large doses of ACTH may require larger amounts of hyaluronidase for equivalent dispersing effect; these drugs render tissues partly resistant to hyaluronidase action. The mechanism involves tissue resistance to hyaluronidase action. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Repository Corticotropin Class
- Adrenocorticotropic Hormone
- Hyaluronidase Class
- Endoglycosidase
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Tissue resistance to hyaluronidase action
What To Tell Your Doctor or Pharmacist
If you are taking Repository Corticotropin and your doctor is considering prescribing Hyaluronidase (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider